Elicio Therapeutics Target of Unusually Large Options Trading (NASDAQ:ELTX)

Posted by on Jun 15th, 2026

Elicio Therapeutics, Inc. (NASDAQ:ELTX – Get Free Report) was the recipient of some unusual options trading activity on Monday. Traders acquired 8,943 call options on the stock. This is an increase of approximately 1,664% compared to the average daily volume of 507 call options.

Elicio Therapeutics Stock Performance

Shares of ELTX stock traded down $10.79 during mid-day trading on Monday, reaching $4.07. The stock had a trading volume of 8,014,811 shares, compared to its average volume of 202,040. The business’s fifty day moving average is $11.36 and its 200-day moving average is $9.96. The company has a current ratio of 2.24, a quick ratio of 2.24 and a debt-to-equity ratio of 5.75. The firm has a market cap of $77.58 million, a price-to-earnings ratio of -1.69 and a beta of 1.13. Elicio Therapeutics has a 1-year low of $3.62 and a 1-year high of $16.00.

Elicio Therapeutics (NASDAQ:ELTX – Get Free Report) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.16). On average, research analysts forecast that Elicio Therapeutics will post -2.09 earnings per share for the current year.

Institutional Investors Weigh In On Elicio Therapeutics

Several hedge funds have recently added to or reduced their stakes in ELTX. Royal Bank of Canada purchased a new stake in Elicio Therapeutics in the first quarter valued at $225,000. Jane Street Group LLC purchased a new stake in Elicio Therapeutics in the first quarter valued at $92,000. Geode Capital Management LLC grew its holdings in Elicio Therapeutics by 56.0% during the second quarter. Geode Capital Management LLC now owns 120,831 shares of the company’s stock worth $933,000 after acquiring an additional 43,364 shares during the period. Raymond James Financial Inc. acquired a new stake in Elicio Therapeutics during the second quarter worth about $46,000. Finally, Vanguard Group Inc. boosted its stake in shares of Elicio Therapeutics by 4.2% in the third quarter. Vanguard Group Inc. now owns 473,859 shares of the company’s stock worth $5,184,000 after acquiring an additional 19,240 shares during the last quarter. 35.03% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. Wall Street Zen cut Elicio Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Elicio Therapeutics in a report on Friday, April 24th. B. Riley Financial assumed coverage on Elicio Therapeutics in a report on Wednesday, June 10th. They issued a “buy” rating and a $27.00 target price for the company. Rodman & Renshaw reiterated a “buy” rating on shares of Elicio Therapeutics in a report on Monday. Finally, HC Wainwright upped their target price on Elicio Therapeutics from $17.00 to $23.00 and gave the stock a “buy” rating in a report on Monday. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $21.75.

Get Our Latest Stock Analysis on ELTX

About Elicio Therapeutics

(Get Free Report)

Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.

Read More

Receive News & Ratings for Elicio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elicio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.